In this context, halofuginone represents a promising therapeutic drug that can act at different key points of osteosarcoma progression: on tumor cells by inducing their apoptosis, on tumor microenvironment by inhibiting tumor associated osteolysis and on the metastatic process mainly by inhibiting the TGF-β signaling pathway. Here, TGFB1 is linked to osteosarcoma.